Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21479586 | 0.71 | RAB9A (0.40) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL22835044 | 0.69 | — | — | |
| SCHEMBL9911990 | 0.67 | RAB9A (0.49) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL17494888 | 0.65 | RAB9A (0.44) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL4406506 | 0.65 | — | — | |
| SCHEMBL13680580 | 0.64 | RAB9A (0.39) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL17494864 | 0.63 | RAB9A (0.56) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL5030822 | 0.63 | RAB9A (0.42) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL21737503 | 0.62 | MYC (0.39) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL3051505 | 0.62 | RAB9A (0.48) | RAB9ASMN1; SMN2GAANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275600-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2017-09-28 | — | — | US | disclosed |
| US-9677055-B2 | Modified forms of Pseudomonas exotoxin A | INTERXON CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170037386-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2017-02-09 | — | — | US | disclosed |
| EP-1601642-B1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2463269-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9447387-B2 | Modified forms of pseudomonas exotoxin A | INTREXON CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-9371517-B2 | Modified forms of Pseudomonas exotoxin A | INTREXON CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-20160108377-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2016-04-21 | — | — | US | disclosed |
| EP-2460786-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20150291941-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150240244-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2015-08-27 | — | — | US | disclosed |
| US-8932586-B2 | Modified forms of Pseudomonas exotoxin A | INTREXON CORPORATION (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130121983-A1 | Modified Forms of Pseudomonas Exotoxin A | INTREXON CORPORATION (US) | 2013-05-16 | — | — | US | disclosed |
| EP-2463269-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2460786-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275600-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | CD4, CD47, CD14 | RAB9A 1077/4885SMN1; SMN2 4752/4885GAA 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.